Marvel Announces Final Shank3 Data: MB-204 Highly Effective at Reversing Autism Behaviours
High-dose MB-204 normalized six mouse behavioural measures that Istradefylline did not; Marvel is preparing for Phase 1 testing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Marvel Biosciences (MBCOF) reported preliminary mouse-study results showing MB-204 normalized multiple behavioural measures in a genetic model associated with autism. In the Shank3 model, high-dose MB-204 returned six measures to normal control-mouse levels that comparator Istradefylline did not normalize. These covered social-contact measures and Y-maze behaviours. Both treatments also normalized grooming episodes and same-arm returns, measures of repetitive behaviour. Low-dose MB-204 normalized several measures as well.
Marvel said the findings support advancing MB-204 toward Phase 1 clinical evaluation; these are preclinical results, not patient outcomes. Separately, Marvel engaged Outside The Box Capital for $50,000 plus applicable taxes and Investing News Network for $45,000 in investor communications services. Both agreements remain subject to TSX Venture Exchange acceptance.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Marvel is preparing Phase 1 clinical testing of MB-204 following the preclinical findings.
- Minor pointHigh-dose MB-204 normalized six social-contact and Y-maze measures that Istradefylline did not normalize.
- Minor pointHigh-dose MB-204 and Istradefylline both normalized grooming episodes and same-arm returns.
- Minor pointLow-dose MB-204 normalized nose/paw contact duration, grooming episodes, spontaneous alternations, alternate-arm returns and same-arm returns.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Outside The Box Capital engagement costs $50,000 plus applicable taxes for October 22–December 21, 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.Investing News Network engagement costs $45,000 for six months, or until inventory is finished.
- Minor pointBoth marketing agreements remain subject to TSX Venture Exchange acceptance.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CALGARY, Alberta, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to share part of the preliminary data set from its preclinical Shank 3Δex13-16 mouse model study (clinically manifests as Phelan-McDermid syndrome) conducted in collaboration with Dr. Julie Le Merrer and Dr. Jerome Becker at the iBraiN Institute.
The findings represent an important milestone in the development of MB-204, with the compound demonstrating the ability to normalize multiple disease-associated behavioural abnormalities. Importantly, high-dose MB-204 demonstrated broader efficacy than Istradefylline, its parent compound, returning six measured behavioural endpoints to wild-type levels, while Istradefylline failed to achieve normalization across those same measures. The results provide further evidence supporting the potential therapeutic advantages of MB-204 and reinforce the Company's rationale for advancing the compound into Phase 1 clinical evaluation.
The study evaluated MB-204, Marvel’s lead compound (1, 2.5 mg/kg per oral), in comparison to Istradefylline (1 mg/kg per oral, the highest dose that does not affect locomotion). Animals were studied one to three hours post dosing. Istradefylline is a clinically approved drug for the treatment of Parkinson’s Disease.
Key Data Highlights:
- High Dose of MB-204 returned behaviour to wild type (normal) levels on the number of nose contacts, the number of paw contacts, the mean duration of nose contacts, the mean duration of paw contacts, the number of spontaneous alternation (SPAs) in the Y-maze and the number of alternate arm returns (AARs).
- Istradefylline did not return behaviour to wild type levels on the number of nose contacts (p<0.001), the number of paw contacts (p<0.05), the mean duration of nose contacts (p<0.001), the mean duration of paw contacts (p<0.05), the number of spontaneous alternation in the Y-maze (p<0.001) and the number of alternate arm returns (p<0.01).
- Both high dose of MB-204 and Istradefylline reduced the number of grooming episodes (a repetitive behaviour) and the number of same arm returns in the Y-maze (SARs: also a repetitive behaviour) to normal levels.
- Low dose MB-204 returned behaviour to normal levels on the mean duration of nose and paw contacts, the number of grooming episodes and on the number of SPAs, AARs and SARs in the Y-maze. On other endpoints, the low dose performed similarly to Istradefylline.
“We are very pleased with the results”, commented Marvel Chief Science Officer Dr. Mark Williams “which confirms the efficacy of MB-204 as a potential first and best-in-class treatment for autism. We look forward to testing MB-204 for the first time in patients as we prepare for our Phase 1 clinical trial.”
Significance of the Shank3 Preclinical Model
The Shank 3Δex13-16 model is particularly relevant to Marvel's development program given its association with Phelan-McDermid syndrome, a rare genetic neurodevelopmental disorder frequently characterized by autism-related symptoms and behavioural abnormalities. Evaluating MB-204 in this model provides an opportunity to investigate its activity across multiple behavioural domains associated with genetically defined forms of autism. The breadth of behavioural improvements observed in this study, together with the comparative results against Istradefylline, adds to the growing preclinical rationale for MB-204 and supports further investigation of its potential across autism and related neurodevelopmental conditions.
Shank3 Preclinical Study – Video Demonstrations
To further illustrate the study findings, the Company has made available three video demonstrations providing visual insight into the Shank3 preclinical model and the observed effects of MB-204. The videos include: (1) video demonstrating normal behavioural interactions in wild-type (control) mice, (2) a demonstration of Shank3-associated behaviours in the preclinical model; and (3) a demonstration of the effects of MB-204 on Shank3-associated behaviours, highlighting the observed behavioural improvements following treatment.
Video 1: Normal Behaviour – Wild-Type Control at this link
Video 2: Shank3 Preclinical Model can be viewed at this link
Video 3: Effect of MB-204 on Shank3 can be viewed at this link
Marketing Engagements
The Company also announces expanded investor awareness and digital marketing initiatives as it advances its lead drug candidate, MB-204, toward Phase 1 clinical trials. With MB-204 progressing toward an important clinical development milestone, the Company is expanding its communications reach to increase awareness of its scientific platform, development progress and potential therapeutic opportunities among a broader investment audience.
The Company announces that it has engaged Outside The Box Capital Inc. ("OTB") of Oakville, Ontario as part of its awareness efforts to provide digital communications services under a marketing services agreement dated October 22, 2026 (the "OTB Agreement"), with services and promotional activity to commence on or after October 22, 2026. Under the OTB Agreement, OTB will distribute Company content, including video, and conduct investor communications on social media. The Agreement has a term of two (2) months, from October 22, 2026, to December 21, 2026. For its services, the Company has agreed to pay OTB a total cash fee of
The Company announces that it has engaged Investing News Network – INN (Dig Media Inc.) (“INN”) to provide digital campaigns and other investor relations activities on behalf of the Company dated October 30, 2026 (the “INN Agreement”), with the campaign commencing on or around October 30, 2026, and continuing for a 6-month period, or until the inventory is finished, and will not automatically renew. INN has been providing independent news and education to investors since 2007 at www.investingnews.com. The services may include news distribution and promotional content through email, social media and other digital channels to a targeted investor audience, including company profile, lead generation, content channels, press release syndication, news marketing, ads, notifications and interviews distributed across INN’s channels and YouTube, and articles distributed through syndicates. In accordance with the terms and conditions of the INN Service Agreement and as consideration for the services provided by INN, the Company has agreed to provide INN with a cash fee of
About Marvel Biosciences Corp.
Marvel Biosciences Corp. (TSXV:MRVL | OTCQB:MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pharmaceutical development biotechnology company entering Phase 1 clinical stage. The Company is developing MB-204, a novel fluorinated derivative of the approved anti-Parkinson’s drug Istradefylline, the only clinically approved adenosine A2a antagonist. A significant and growing body of scientific evidence suggests drugs that block the adenosine A2a receptor, such as MB-204, could be useful in treating other neurological diseases such as autism, depression and Alzheimer’s Disease. The Company is actively investigating its potential in addressing other neurodevelopmental disorders, such as Rett Syndrome and Fragile X Syndrome, to expand its therapeutic reach.
Contact Information: Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer
Email: rod@marvelbiosciences.com
Dr. Mark Williams, President and Chief Science Officer
Email: mark@marvelbiosciences.com
Tel: 403 770 2469
Website: www.marvelbiotechnology.com | Twitter/X | LinkedIn
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party.
This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Marvel Biosciences report about MB-204 in the Shank3 mouse study?
High-dose MB-204 returned six behavioural measures to normal control-mouse levels that Istradefylline did not normalize. These included the number and mean duration of nose and paw contacts, spontaneous alternations in the Y-maze, and alternate-arm returns. The findings are preliminary preclinical data.
What is the next development step for Marvel Biosciences' MB-204?
Marvel is preparing for Phase 1 clinical evaluation of MB-204. The company views the mouse-study findings as support for advancing the compound into clinical testing.
What doses and observation window were used in Marvel Biosciences' MB-204 mouse study?
The study evaluated oral MB-204 at 1 and 2.5 mg/kg against oral Istradefylline at 1 mg/kg, with animals studied one to three hours after dosing. The Istradefylline dose was the highest that does not affect locomotion.